| Role of H-ras gene in chronic liver damage in mice. By using transgenic mice carrying a human C-H-ras proto-oncogene without mutations. | liver, |
| Alterations of level of total genomic DNA methylation and pattern of c-myc, c-Ha-ras oncogene methylation in human gastric carcinogenesis. | gastric, |
| Oncogenic c-Ki-ras but not oncogenic c-Ha-ras up-regulates CEA expression and disrupts basolateral polarity in colon epithelial cells. | colorectal, |
| H-ras oncogene activation in invasive UVR-induced corneal sarcomas of the opossum Monodelphis domestica. | sarcoma, |
| In vivo effects of activated H-ras oncogene expressed in the liver and in urogenital tissues. | liver, |
| Transforming and oncogenic potential of activated c-Ha-ras in three immortalized human breast epithelial cell lines. | breast, |
| Variability of Ha-ras (codon 12) proto-oncogene mutations in diverse thyroid cancers. | thyroid, |
| Nuclear and nucleolar image analysis of human breast epithelial cells transformed by benzo[a]pyrene and transfected with the c-Ha-ras oncogene. | breast, |
| Genetic analysis of the rat leukemia virus: influence of viral sequences in transduction of the c-ras proto-oncogene and expression of its transforming activity. | leukemia, |
| Selective activation of Ha-ras(val12) oncogene increases susceptibilityof NIH/3T3 cells to TNF-alpha. | None |
| A cycloplatinated compound of p-isopropylbenzaldehyde thiosemicarbazone and its chloro-bridged derivative induce apoptosis in cis-DDP resistant cells which overexpress the H-ras oncogene. | None |
| Malignant fibrous histiocytomas and H-ras-1 oncogene point mutations. | None |
| Hepatitis C virus nonstructural protein NS4B transforms NIH3T3 cells in cooperation with the Ha-ras oncogene. | None |
| NF-kappa B is required for H-ras oncogene induced abnormal cell proliferation and tumorigenesis. | None |
| Lack of susceptibility of transgenic mice carrying the human c-Ha-ras proto-oncogene (rasH2 mice) to phenolphthalein in a 6-month carcinogenicity study. | None |
| Theophylline and cisplatin synergize in down regulation of BCL-2 induction of apoptosis in human granulosa cells transformed by a mutated p53 (p53 val135) and Ha-ras oncogene. | None |
| Evidence that error-prone DNA repair converts dibenzo[a,l]pyrene-induced depurinating lesions into mutations: formation, clonal proliferation and regression of initiated cells carrying H-ras oncogene mutations in early preneoplasia. | None |
| Down-regulation of alpha6 integrin, an anti-oncogene product, by functional cooperation of H-Ras and c-Myc. | None |
| Role of the cytosolic phospholipase A2-linked cascade in signaling by an oncogenic, constitutively active Ha-Ras isoform. | None |
| High susceptibility of transgenic rats carrying the human c-Ha-ras proto-oncogene to chemically-induced mammary carcinogenesis. | None |